Eurofins Medinet strengthens US leadership team by appointing Doug Toal

November 6 2008, Washington DC

Eurofins Medinet is pleased to announce the addition of Doug Toal, Ph.D. (ABMM) as Director of Microbiology Operations on November 3, 2008. Dr. Toal will lead the microbiology operations at the Eurofins Medinet laboratory in Washington DC, reporting to Dan Sahm, President of Eurofins Medinet, Inc.  Dr. Toal brings over 12 years of experience in managing and directing commercial laboratories and is certified by the American Board of Medical Microbiology. Most recently Doug was the Regional Operations Director at EMLab P&K in Cherry Hill, New Jersey where he managed six locations in the eastern U.S. He worked closely with Project Managers, Lab Managers, and reviewed and approved Quality SOPs to make sure all facilities operated in a compliant manner and exceeded customer expectations.

Dr. Toal has worked in Austin, Texas for Severn Trent Laboratories where he was Laboratory Director & Quality Assurance Manager. He was a key contributor to developing and implementing sales strategies and meeting budgetary goals.  He also served as the Director of Clinical Microbiology at DynaCare Laboratories in Birmingham, Alabama directing bacteriology, virology, mycology, molecular biology, and mycobacteriology of a medical reference laboratory. Doug’s vast experience in microbiology and large commercial laboratories make him a great asset to our organization. We look forward to working with Doug and getting to know him and tapping in to his wide knowledge base.

Doug received his Bachelor of Science from Oral Roberts University in Tulsa, Oklahoma where he earned his Masters of Biomedical Science, Microbiology. He also received his Doctor of Philosophy, Microbiology from the University of Oklahoma, in Norman, Oklahoma. He was a Postdoctoral Fellow at the Mayo Clinic in Rochester, Minnesota where he received training in all aspects of diagnostic microbiology. Some of his strongest competencies include Quality Assurance, strategic planning, technical writing, client service, and cost containment just to name a few.  

For more information about Eurofins Medinet, please visit us online at www.eurofinsmedinet.com or contact: 

Eurofins Medinet Washington DC

Tel: +1 703 480-2500

Fax: +1 703 480-2654

Email: info@eurofinsmedinet.com 

Notes for the editor:

About Eurofins – a global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.With about 7,000 staff in more than 150 laboratories across 29 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff.

The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on NYSE Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE). 

About Eurofins Medinet

Eurofins Medinet provides a full range of global central laboratory testing services including safety parameters, biomarker development and analysis, and specialized testing in bioanalysis, pharmacokinetics, microbiology and genomics using its fully standardized and accredited central laboratories in the Netherlands, USA (two laboratories), France, Singapore and China.

 

Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.
Dernière mise à jour par: Daniel Quick
Dernière mise à jour: vendredi 4 janvier 2013